Drug Type Antibody drug conjugate (ADC) |
Synonyms BA 1302, BA1302 |
Target |
Action inhibitors |
Mechanism CD228 inhibitors(Melanotransferrin inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced breast cancer | Phase 1 | - | 11 Sep 2024 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 1 | - | 11 Sep 2024 | |
Advanced Malignant Solid Neoplasm | Phase 1 | - | 11 Sep 2024 | |
Metastatic melanoma | Phase 1 | - | 11 Sep 2024 | |
Pancreatic adenocarcinoma | Phase 1 | - | 11 Sep 2024 | |
Breast Cancer | Phase 1 | China | - | |
Colorectal Cancer | Phase 1 | China | - | |
Non-Small Cell Lung Cancer | Phase 1 | China | - | |
Pancreatic Cancer | Phase 1 | China | - |